Medicine & Life Sciences
Cost-Benefit Analysis
100%
Randomized Controlled Trials
66%
Costs and Cost Analysis
44%
Stress Urinary Incontinence
42%
Quality-Adjusted Life Years
41%
Suburethral Slings
39%
Urinary Incontinence
35%
Pelvic Floor
32%
Systematic Reviews
31%
Prolapse
23%
Lithotripsy
21%
Uterine Prolapse
21%
Artificial Urinary Sphincter
19%
Prostate
19%
Conservative Treatment
19%
Non-Randomized Controlled Trials
19%
Confidence Intervals
18%
Random Allocation
17%
Tamsulosin
16%
Muscles
16%
Hemorrhoidectomy
16%
Economics
16%
Placebos
15%
Urodynamics
14%
Quality of Life
14%
Transurethral Resection of Prostate
14%
Catheters
14%
Therapeutics
14%
Nifedipine
14%
Prostatectomy
13%
Root Caries
13%
Medication Therapy Management
13%
Pelvic Organ Prolapse
12%
Catheterization
12%
Biofeedback (Psychology)
11%
Cholecystitis
10%
Inlays
10%
Nitrofurazone
10%
Catheter-Related Infections
10%
National Institutes of Health (U.S.)
10%
Scotland
10%
Urinary Tract Infections
10%
Uncertainty
9%
OPAL protocol
9%
Gallstones
9%
Calcium Channel Blockers
9%
Cholecystectomy
9%
Ureter
8%
Ureteroscopy
8%
Odds Ratio
7%
Social Sciences
costs
42%
surgery
34%
confidence
17%
life years
17%
management
14%
economics
11%
current management
10%
utility analysis
8%
Group
8%
quality of life
8%
evaluation
7%
adverse events
6%
drug therapy
6%
evidence
6%
health
6%
pragmatics
5%
heart disease
5%
